Register entry
UCB, Inc.
- Registered sites
- 2
- Drug products
- 65
- Live patents
- 99
- Countries
- 2
- Base
- Belgium
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Analytical testingActive ingredient (API) manufactureLabellingFinished drug manufacturePackagingRelabellingRepackagingsterilize
Sites
Facilities
2| Site | Location | Operations | FEI |
|---|---|---|---|
| UCB Pharma S.A. | Braine-l'AlleudBelgium | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging, Relabelling, Repackaging | 3003909356 |
| UCB Farchim S.A. | BulleSwitzerland | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging, Relabelling, Repackaging, sterilize | 3005023799 |
Exclusivity
Patents
99Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| BRIVIACT | BRIVARACETAM | Apr 2030 |
| FINTEPLA | FENFLURAMINE HYDROCHLORIDE | May 2033 |
| FINTEPLA | FENFLURAMINE HYDROCHLORIDE | Nov 2033 |
| FINTEPLA | FENFLURAMINE HYDROCHLORIDE | Dec 2036 |
| FINTEPLA | FENFLURAMINE HYDROCHLORIDE | Jun 2037 |
| FINTEPLA | FENFLURAMINE HYDROCHLORIDE | Aug 2037 |
| FINTEPLA | FENFLURAMINE HYDROCHLORIDE | Feb 2038 |
| FINTEPLA | FENFLURAMINE HYDROCHLORIDE | Dec 2038 |
| KEPPRA | LEVETIRACETAM | Jun 2031 |
| KEPPRA | LEVETIRACETAM | Dec 2031 |
| KEPPRA XR | LEVETIRACETAM | Sept 2028 |
| KYGEVVI | DOXECITINE; DOXRIBTIMINE | Aug 2036 |
| KYGEVVI | DOXECITINE; DOXRIBTIMINE | Aug 2040 |
| NAYZILAM | MIDAZOLAM | Jan 2028 |
| NEUPRO | ROTIGOTINE | Sept 2027 |
| NEUPRO | ROTIGOTINE | Dec 2030 |
| NEUPRO | ROTIGOTINE | Mar 2032 |
| ZILBRYSQ | ZILUCOPLAN SODIUM | Jun 2035 |
Catalogue
Marketed products
65Showing 65 of 65.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| - | BRIVARACETAM | TABLET, FILM COATED | DRUG FOR FURTHER PROCESSING |
| - | BRIVARACETAM | TABLET, FILM COATED | DRUG FOR FURTHER PROCESSING |
| - | BRIVARACETAM | TABLET, FILM COATED | DRUG FOR FURTHER PROCESSING |
| - | BRIVARACETAM | TABLET, FILM COATED | DRUG FOR FURTHER PROCESSING |
| - | BRIVARACETAM | TABLET, FILM COATED | DRUG FOR FURTHER PROCESSING |
| Bimzelx | bimekizumab | INJECTION, SOLUTION | BLA |
| Bimzelx | bimekizumab | INJECTION, SOLUTION | BLA |
| Bimzelx | bimekizumab | INJECTION, SOLUTION | BLA |
| Bimzelx | bimekizumab | INJECTION, SOLUTION | BLA |
| Briviact | brivaracetam | TABLET, FILM COATED | NDA |
| Briviact | brivaracetam | TABLET, FILM COATED | NDA |
| Briviact | brivaracetam | TABLET, FILM COATED | NDA |
| Briviact | brivaracetam | TABLET, FILM COATED | NDA |
| Briviact | brivaracetam | TABLET, FILM COATED | NDA |
| Briviact | brivaracetam | SOLUTION | NDA |
| Briviact | brivaracetam | INJECTION, SUSPENSION | NDA |
| Cimzia | certolizumab pegol | KIT | BLA |
| Cimzia | certolizumab pegol | INJECTION, SOLUTION | BLA |
| Cimzia | certolizumab pegol | INJECTION, SOLUTION | BLA |
| Fintepla | fenfluramine | SOLUTION | NDA |
| KYGEVVI | doxecitine and doxribtimine | POWDER, FOR SOLUTION | NDA |
| Keppra | levetiracetam | SOLUTION | NDA |
| Keppra | levetiracetam | INJECTION, SOLUTION, CONCENTRATE | NDA |
| Keppra | levetiracetam | TABLET, FILM COATED | NDA |
| Keppra | levetiracetam | TABLET, FILM COATED | NDA |
| Keppra | levetiracetam | TABLET, FILM COATED | NDA |
| Keppra | levetiracetam | TABLET, FILM COATED | NDA |
| Keppra XR | levetiracetam | TABLET, FILM COATED, EXTENDED RELEASE | NDA |
| Keppra XR | levetiracetam | TABLET, FILM COATED, EXTENDED RELEASE | NDA |
| Nayzilam | midazolam | SPRAY | NDA |
| Neupro | rotigotine | PATCH, EXTENDED RELEASE | NDA |
| Neupro | rotigotine | PATCH, EXTENDED RELEASE | NDA |
| Neupro | rotigotine | PATCH, EXTENDED RELEASE | NDA |
| Neupro | rotigotine | PATCH, EXTENDED RELEASE | NDA |
| Neupro | rotigotine | PATCH, EXTENDED RELEASE | NDA |
| Neupro | rotigotine | PATCH, EXTENDED RELEASE | NDA |
| Neupro | rotigotine | KIT | NDA |
| RYSTIGGO | ROZANOLIXIZUMAB | INJECTION, SOLUTION | BLA |
| RYSTIGGO | ROZANOLIXIZUMAB | INJECTION, SOLUTION | BLA |
| RYSTIGGO | ROZANOLIXIZUMAB | INJECTION, SOLUTION | BLA |
| RYSTIGGO | ROZANOLIXIZUMAB | INJECTION, SOLUTION | BLA |
| Vimpat | lacosamide | INJECTION | NDA |
| Vimpat | lacosamide | TABLET, FILM COATED | NDA |
| Vimpat | lacosamide | TABLET, FILM COATED | NDA |
| Vimpat | lacosamide | TABLET, FILM COATED | NDA |
| Vimpat | lacosamide | TABLET, FILM COATED | NDA |
| Vimpat | lacosamide | SOLUTION | NDA |
| ZILBRYSQ | zilucoplan | INJECTION, SOLUTION | NDA |
| ZILBRYSQ | zilucoplan | INJECTION, SOLUTION | NDA |
| ZILBRYSQ | zilucoplan | INJECTION, SOLUTION | NDA |
| - | brivaracetam | POWDER | BULK INGREDIENT |
| - | cetirizine hydrochloride and pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE | DRUG FOR FURTHER PROCESSING |
| - | lacosamide | POWDER | BULK INGREDIENT |
| - | lacosamide | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | lacosamide | TABLET, FILM COATED | DRUG FOR FURTHER PROCESSING |
| - | lacosamide | TABLET, FILM COATED | DRUG FOR FURTHER PROCESSING |
| - | lacosamide | TABLET, FILM COATED | DRUG FOR FURTHER PROCESSING |
| - | lacosamide | TABLET, FILM COATED | DRUG FOR FURTHER PROCESSING |
| - | levetiracetam | POWDER | BULK INGREDIENT |
| - | levetiracetam | TABLET, FILM COATED | DRUG FOR FURTHER PROCESSING |
| - | levetiracetam | TABLET, FILM COATED | DRUG FOR FURTHER PROCESSING |
| - | levetiracetam | TABLET, FILM COATED | DRUG FOR FURTHER PROCESSING |
| - | levetiracetam | TABLET, FILM COATED | DRUG FOR FURTHER PROCESSING |
| - | levetiracetam | TABLET, FILM COATED, EXTENDED RELEASE | DRUG FOR FURTHER PROCESSING |
| - | levetiracetam | TABLET, FILM COATED, EXTENDED RELEASE | DRUG FOR FURTHER PROCESSING |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.